Merck's Q3 Strength Sparks Caution, Not Conviction

What happened

Merck reported Q3 2026 revenue up 8.9% sequentially, driven by Keytruda and Winrevair. Keytruda+Qlex sales rose 5.6% YoY to $8.1B, and Winrevair grew 18% QoQ to $694M. Despite these results, the article's cautionary headline and Merck's unresolved structural risks (Keytruda LOE, Gardasil China pause) warrant scrutiny. The master report rated MRK a WAIT with a $125 base-case value, hinging on a contained $2.5B FY2026 erosion and China restart signals. The Q3 data confirms near-term operating momentum but does not yet resolve the 2028–2029 Keytruda transition or China vaccine recovery uncertainty.

Implication

Investors should treat the Q3 beat as confirmation of the base-case trajectory rather than a re-rating catalyst, as the Keytruda concentration and dated exclusivity cliffs remain unchanged. The sequential revenue growth of 8.9% aligns with the master report's expectation of flat-to-low growth in 2026, given the $2.5B headwind; Keytruda's 5.6% YoY growth is steady but not accelerating. Winrevair's 18% sequential growth is a positive early indicator for the post-Keytruda pipeline, but its $694M quarterly run-rate still needs to scale meaningfully to offset upcoming LOE events. The most critical unresolved issues—China Gardasil shipment restart timing and the FY2026 headwind quantification—remain open, and Q3 did not provide updates; until those are clarified, the stock likely remains rangebound between $105 and $135. Therefore, existing holders should trim above $135, new money should wait for a pullback toward $105, and all investors should re-assess after the next earnings call when management comments on the headwind and China signals.

Thesis delta

The Q3 results reinforce the base-case operating outcome but do not materially alter the investment thesis. Keytruda continues to grow modestly, and Winrevair shows promising trajectory, yet the core risks—LOE and China vaccine uncertainty—are unchanged. Consequently, the WAIT rating and $125 base-case value remain appropriate, with no immediate shift to BUY or SELL.